EARLY STRUCTURAL AND FUNCTIONAL CARDIAC CHANGES IN METABOLIC SYNDROME: FROM DIFFUSE MYOCARDIAL FIBROSIS TO HEART FAILURE WITH PRESERVED EJECTION FRACTION

Authors

Keywords:

metabolic syndrome, diffuse myocardial fibrosis, heart failure with preserved ejection fraction, extracellular volume fraction, diastolic dysfunction, T1 mapping, cardiac remodeling

Abstract

Background and Objective: Metabolic syndrome (MetS) affects approximately one-quarter of the global adult population and is increasingly recognized as a potent driver of subclinical cardiac remodeling that ultimately culminates in heart failure with preserved ejection fraction (HFpEF). Despite the well-established epidemiological association between MetS and HFpEF, the precise temporal sequence of early structural and functional cardiac alterations — particularly the role of diffuse myocardial fibrosis as a mechanistic bridge — remains incompletely characterized. The primary objective of this study was to comprehensively evaluate early cardiac structural and functional changes in patients with MetS who have not yet developed overt heart failure, with particular emphasis on quantifying diffuse myocardial fibrosis using cardiac magnetic resonance (CMR) T1 mapping and correlating these findings with echocardiographic indices of diastolic dysfunction.

Methods: This cross-sectional observational study enrolled 360 participants stratified into three groups: MetS without cardiovascular symptoms (n=140), MetS with evidence of diastolic dysfunction (n=120), and age- and sex-matched healthy controls (n=100). All participants underwent comprehensive transthoracic echocardiography with speckle-tracking strain analysis, CMR with native T1 mapping and extracellular volume (ECV) fraction quantification, and serum biomarker assessment including high-sensitivity cardiac troponin T (hs-cTnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), galectin-3, and soluble suppression of tumorigenicity 2 (sST2).

Results: Native T1 values and ECV fractions increased stepwise from healthy controls (1,018 ± 25 ms; 26.2 ± 2.1%) to asymptomatic MetS patients (1,058 ± 33 ms; 29.1 ± 3.2%) and MetS patients with diastolic dysfunction (1,082 ± 38 ms; 31.4 ± 3.8%; p<0.001 for all pairwise comparisons), indicating diffuse interstitial fibrosis even in the absence of clinical symptoms. Global longitudinal strain (GLS) was significantly impaired in both MetS groups despite preserved left ventricular ejection fraction (LVEF). ECV fraction demonstrated the strongest independent correlation with E/e' ratio (r=0.72, p<0.001) and was an independent predictor of diastolic dysfunction after multivariable adjustment (OR = 1.42 per 1% increase; AUC = 0.84). Galectin-3 levels were significantly elevated across both MetS groups and correlated positively with ECV fraction.

Conclusion: Diffuse myocardial fibrosis, detectable by CMR-derived ECV quantification, represents an early and potentially reversible structural hallmark of MetS-related cardiac remodeling that precedes and mechanistically contributes to the development of diastolic dysfunction and ultimately HFpEF. Integration of advanced imaging biomarkers with circulating fibrosis markers may enable earlier identification and targeted intervention in at-risk populations.

 

References

1.Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., ... & Smith, S. C. (2009). Harmonizing the metabolic syndrome: a joint interim statement. Circulation, 120(16), 1640–1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644

2.Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., ... & Packer, M. (2021). Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 385(16), 1451–1461. https://doi.org/10.1056/NEJMoa2107038

3.Borlaug, B. A. (2014). The pathophysiology of heart failure with preserved ejection fraction. Nature Reviews Cardiology, 11(9), 507–515. https://doi.org/10.1038/nrcardio.2014.83

4.Cavalera, M., Wang, J., & Frangogiannis, N. G. (2014). Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Translational Research, 164(4), 323–335. https://doi.org/10.1016/j.trsl.2014.05.001

5.de Boer, R. A., Voors, A. A., Muntendam, P., van Gilst, W. H., & van Veldhuisen, D. J. (2009). Galectin-3: a novel mediator of heart failure development and progression. European Journal of Heart Failure, 11(9), 811–817. https://doi.org/10.1093/eurjhf/hfp097

6.Ernande, L., Bergerot, C., Girerd, N., Thibault, H., Davidsen, E. S., Pignon-Blanc, P. G., ... & Derumeaux, G. (2014). Longitudinal myocardial strain alteration is associated with left ventricular remodeling in asymptomatic patients with type 2 diabetes mellitus. Journal of the American Society of Echocardiography, 27(5), 479–488. https://doi.org/10.1016/j.echo.2014.01.001

7.Haass, M., Kitzman, D. W., Anand, I. S., Miller, A., Zile, M. R., Massie, B. M., & Carson, P. E. (2011). Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction. Circulation: Heart Failure, 4(3), 324–331. https://doi.org/10.1161/CIRCHEARTFAILURE.110.959890

8.Levelt, E., Mahmod, M., Piechnik, S. K., Aber, S., Francis, J. M., Burke, K., ... & Neubauer, S. (2016). Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes. Diabetes, 65(1), 44–52. https://doi.org/10.2337/db15-0627

9.Madamanchi, C., Alhosaini, H., Sumida, A., & Runge, M. S. (2014). Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. International Journal of Cardiology, 176(3), 611–617. https://doi.org/10.1016/j.ijcard.2014.08.007

10.Messroghli, D. R., Moon, J. C., Ferreira, V. M., Grosse-Herrenthey, A., He, T., Kellman, P., ... & Schulz-Menger, J. (2017). Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR). Journal of Cardiovascular Magnetic Resonance, 19(1), 75. https://doi.org/10.1186/s12968-017-0389-8

11.Nagueh, S. F., Smiseth, O. A., Appleton, C. P., Byrd, B. F., Dokainish, H., Edvardsen, T., ... & Houston, T. (2016). Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the ASE and the EACVI. Journal of the American Society of Echocardiography, 29(4), 277–314. https://doi.org/10.1016/j.echo.2016.01.011

12.Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017). Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation, 136(1), 6–19. https://doi.org/10.1161/CIRCULATIONAHA.116.026807

13.Packer, M., & Kitzman, D. W. (2018). Obesity-related heart failure with a preserved ejection fraction: the mechanistic rationale for combining inhibitors of aldosterone, neprilysin, and sodium-glucose cotransporter-2. JACC: Heart Failure, 6(8), 633–639. https://doi.org/10.1016/j.jchf.2018.01.009

14.Pandey, A., LaMonte, M., Klein, L., Ayers, E., Psaty, B. M., Eaton, C. B., ... & Berry, J. D. (2017). Relationship between physical activity, body mass index, and risk of heart failure. Journal of the American College of Cardiology, 69(9), 1129–1142. https://doi.org/10.1016/j.jacc.2016.11.081

15.Paulus, W. J., & Tschöpe, C. (2013). A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Journal of the American College of Cardiology, 62(4), 263–271. https://doi.org/10.1016/j.jacc.2013.02.092

16.Rider, O. J., Lewandowski, A., Nethononda, R., Petersen, S. E., Francis, J. M., Pitcher, A., ... & Neubauer, S. (2013). Gender-specific differences in left ventricular remodelling in obesity: insights from cardiovascular magnetic resonance imaging. European Heart Journal, 34(4), 292–299. https://doi.org/10.1093/eurheartj/ehs341

17.Saklayen, M. G. (2018). The global epidemic of the metabolic syndrome. Current Hypertension Reports, 20(2), 12. https://doi.org/10.1007/s11906-018-0812-z

18.Schelbert, E. B., Piehler, K. M., Engel, L. C., Hanna, J. E., DeLong, J. H., Zhong, L., ... & Wong, T. C. (2015). Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection fraction and heart failure stage. Journal of the American Heart Association, 4(12), e002613. https://doi.org/10.1161/JAHA.115.002613

19.Shah, S. J., Katz, D. H., Selvaraj, S., Burke, M. A., Yancy, C. W., Gheorghiade, M., ... & Deo, R. C. (2015). Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation, 131(3), 269–279. https://doi.org/10.1161/CIRCULATIONAHA.114.010637

20.Zile, M. R., Baicu, C. F., Ikonomidis, J. S., Stroud, R. E., Nietert, P. J., Bradshaw, A. D., ... & Spinale, F. G. (2015). Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation, 131(14), 1247–1259. https://doi.org/10.1161/CIRCULATIONAHA.114.013215

Published

2026-11-03